EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma

Aurore Perrot iD, Jérôme Lambert, Cyrille Hulin, Andrea Pieragostini, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre-Barbe, Julie Gay, Thomas Chalopin und 15 weitere

New England Journal of Medicine · 31.07.2025 · 393 (5) · 425-437

DOI: 10.1056/nejmoa2505133 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 31.07.2025. Verfasst von Aurore Perrot und 26 weiteren Autor:innen. Beteiligte Einrichtung: Service Hématologie, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Consolidation Chemotherapy, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsConsolidation ChemotherapyHematopoietic Stem Cell TransplantationMultiple MyelomaAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedDexamethasoneLenalidomideNeoplasm, ResidualOligopeptidesTransplantation, AutologousInduction ChemotherapyTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedcarfilzomibDexamethasoneisatuximabLenalidomideOligopeptides

Autor:innen und Institutionen

  • Service Hématologie, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France.
  • Biostatistics and Medical Information Department, Hôpital St. Louis, Paris.
  • Service d'Hématologie, Hôpital Haut Lévêque, Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France.
  • Service Hématologie, Hôpital Universitaire de Dijon, Dijon, France.
  • Service Hématologie, Hôpital Universitaire Lyon Sud, Pierre-Bénite, France.
  • Hôpital Universitaire St. Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris.

ORCID-Profile: Aurore Perrot, Mohamad Mohty

Förderung

  • NCI NIH HHS

Zitieren

APA

Perrot, A., Lambert, J., Hulin, C., Pieragostini, A., Karlin, L., Arnulf, B., Rey, P., Garderet, L., Macro, M., Escoffre-Barbe, M., Gay, J., Chalopin, T., Gounot, R., Schiano, J. M., Mohty, M., Leleu, X., Manier, S., Mariette, C., Chaleteix, C., …, & MIDAS Study Group (2025). Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma. New England Journal of Medicine, 393(5), 425-437. https://doi.org/10.1056/nejmoa2505133

Vancouver

Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma. New England Journal of Medicine. 2025;393(5):425-437. doi:10.1056/nejmoa2505133

BibTeX
@article{Perrot2025,
  author = {Perrot, Aurore and Lambert, Jérôme and Hulin, Cyrille and Pieragostini, Andrea and Karlin, Lionel and Arnulf, Bertrand and Rey, Philippe and Garderet, Laurent and Macro, Margaret and Escoffre-Barbe, Martine and Gay, Julie and Chalopin, Thomas and Gounot, Romain and Schiano, Jean-Marc and Mohty, Mohamad and Leleu, Xavier and Manier, Salomon and Mariette, Clara and Chaleteix, Carine and Braun, Thorsten and De Prijck, Bernard and Avet-Loiseau, Hervé and Mary, Jean-Yves and Corre, Jill and Moreau, Philippe and Touzeau, Cyrille and MIDAS Study Group, MIDAS Study Group},
  title = {Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {5},
  pages = {425--437},
  doi = {10.1056/nejmoa2505133}
}
Kostenlos starten →